On June 21, 2018, Resaphene Suisse AG completed its IPO on the stock exchange in Vienna in the Third Market segment. This step was necessary to give institutional investors the opportunity for investment. The reference price was set at €516.50.

This also concludes the process of the strategic shift in the financing area. This was initiated in the summer of 2017, as inefficiencies in capital procurement were identified and subsequently eliminated by CFO Thomas Rauterkus.

Overall, Resaphene is thus on the home stretch towards the professionalization of all its processes. The board of directors assumes that the restructuring in the medical technology sales will also be completed in the third quarter of 2018 with the concentration of the business units in the Bodensee region.